Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis

Abstract

Background : Recent studies have shown that circulating long noncoding RNAs (lncRNAs) could be stably detectable in the blood of cancer patients and play important roles in the diagnosis of many different cancers. However, the value of lncRNAs in the diagnosis of pancreatic cancer (PC) has not been fully explored. Methods : Eleven PC-related lncRNAs were selected by analyzing bioinformatics databases. The expression levels of the lncRNAs were further analyzed in a small set of plasma samples from a training group including 30 noncancer samples (15 healthy and 15 chronic pancreatitis (CP) subjects) and 15 PC samples. Then, the candidate lncRNAs were validated with data from 46 healthy controls, 97 CP patients and 114 PC patients. Receiver operating characteristic (ROC) curves were employed to evaluate the diagnostic performance of the identified lncRNAs. Results : After selection and validation, three characteristic plasma candidate lncRNAs, ABHD11-AS1, LINC00176 and SNHG11, were identified, and their levels were significantly higher in PC patients than in normal controls. We found that among the three candidate lncRNAs, ABHD11-AS1 showed the best diagnostic performance for the detection of PC. Furthermore, ABHD11-AS1 had a higher area under the ROC curve (AUC) than CEA, CA199 and CA125 for early PC diagnosis, while the combination of ABHD11-AS1 and CA199 was more effective than ABHD11-AS1 alone. Conclusions : Plasma ABHD11-AS1 could serve as a potential biomarker for detecting PC, and the combination of ABHD11-AS1 and CA199 was more efficient for the diagnosis of PC than ABHD11-AS1 alone, particularly for early tumor screening.

<p>OIP5-AS1/miR-137/ZNF217 Axis Promotes Malignant Behaviors in Epithelial Ovarian Cancer</p>

“…LncRNAs have been found to be aberrantly expressed in various human malignancies, and the abnormal expressed lncRNAs can be used as clinical biomarkers at early diagnosis period. [12][13][14] Recently, OIP5-AS1, as a novel lncRNA, was found to be aberrantly expressed in multiple tumors and could be viewed as a clinical biomarker in bladder cancer and osteosarcoma. 15,16 However, its expression pattern and biological effects on EOC have not been studied yet.…”

Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study

“…However, serum CA199 levels are elevated not only in the case of PC but also in other cancers and certain inflammatory diseases. Therefore, as a diagnostic tool for PDAC, serum CA199 levels have low sensitivity and specificity (Liu et al, 2019;Zeng et al, 2019). Serum CA199 levels mainly reflects the status of the tumor, whereas the CONUT score reflects the overall status of the patient, including nutritional and immune status.…”

Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis

“…The higher expression of UNC5B-AS1, MATAL1 and n340790 was shown to distinguish the tumor and normal samples with AUC values of 0.932, 0.632 and 0.845, respectively (127,130,131). With the increasing identification of diagnostic circulating lncRNAs in different cancers (173)(174)(175)(176)(177), we expect to see the utilization of circulating lncRNAs to optimize diagnostic accuracy of thyroid nodules in the future.…”